Roundtable Discussion: How Antigen-Specific Approaches can be Positioned as a Prophylactic Measure as Well as a Therapeutic Cure
1:00 pm - Thursday 25th March 2027
- Which autoimmune diseases are best suited for the use of antigen-specific therapy once a patient has been diagnosed
- Debate whether the field should prioritize preventing disease in at-risk individuals (Stage 1-2) versus treating established disease (Stage 3)
- Understand why prophylactic clinical trials are challenging (slow enrollment, long duration, high costs) but may offer the best path to demonstrating tolerance efficacy
- Learn from teplizumab’s success as a preventive therapy that delays type 1 diabetes onset by two years
